These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 6934850

  • 1. Studies on the comparative distribution and biliary excretion of doxorubicin and 4'-epi-doxorubicin in mice and rats.
    Broggini M, Colombo T, Martini A, Donelli MG.
    Cancer Treat Rep; 1980; 64(8-9):897-904. PubMed ID: 6934850
    [Abstract] [Full Text] [Related]

  • 2. [A comparative study of 4'-epi-doxorubicin and doxorubicin cardiotoxicities].
    Suzuki T, Yamamoto H, Iwasaki T, Okamoto S, Iizuka T, Kanda H, Murata K.
    Gan To Kagaku Ryoho; 1984 Oct; 11(10):2170-6. PubMed ID: 6593004
    [Abstract] [Full Text] [Related]

  • 3. Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study.
    Camaggi CM, Comparsi R, Strocchi E, Testoni F, Angelelli B, Pannuti F.
    Cancer Chemother Pharmacol; 1988 Oct; 21(3):221-8. PubMed ID: 3162849
    [Abstract] [Full Text] [Related]

  • 4. Epirubicin plasma and blood pharmacokinetics after single i.v. bolus in advanced cancer patients.
    Camaggi CM, Strocchi E, Martoni A, Angelelli B, Comparsi R, Pannuti F.
    Drugs Exp Clin Res; 1985 Oct; 11(4):285-94. PubMed ID: 3869807
    [Abstract] [Full Text] [Related]

  • 5. Doxorubicin and epirubicin cardiotoxicity: experimental and clinical aspects.
    Neri B, Cini-Neri G, Bandinelli M, Pacini P, Bartalucci S, Ciapini A.
    Int J Clin Pharmacol Ther Toxicol; 1989 May; 27(5):217-21. PubMed ID: 2737789
    [Abstract] [Full Text] [Related]

  • 6. Disposition and metabolism of adriamycin octanoylhydrazone (NSC 233853) in mice and rabbits.
    Egorin MJ, Clawson RE, Ross LA, Chou FT, Andrews PA, Bachur NR.
    Drug Metab Dispos; 1981 May; 9(3):240-5. PubMed ID: 6113933
    [Abstract] [Full Text] [Related]

  • 7. 4'-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data.
    Ganzina F.
    Cancer Treat Rev; 1983 Mar; 10(1):1-22. PubMed ID: 6342772
    [Abstract] [Full Text] [Related]

  • 8. Cyclosporin A markedly changes the distribution of doxorubicin in mice and rats.
    Colombo T, Zucchetti M, D'Incalci M.
    J Pharmacol Exp Ther; 1994 Apr; 269(1):22-7. PubMed ID: 8169829
    [Abstract] [Full Text] [Related]

  • 9. Echocardiographic assessment of anthracycline cardiotoxicity during different therapeutic regimens.
    De Leonardis V, De Scalzi M, Neri B, Bartalucci S, Cinelli P.
    Int J Clin Pharmacol Res; 1987 Apr; 7(4):307-11. PubMed ID: 3474215
    [Abstract] [Full Text] [Related]

  • 10. Doxorubicin and daunorubicin plasmatic, hepatic and renal disposition in the rabbit with or without enterohepatic circulation.
    Maniez-Devos DM, Baurain R, Lesne M, Trouet A.
    J Pharmacol; 1986 Apr; 17(1):1-13. PubMed ID: 3713196
    [Abstract] [Full Text] [Related]

  • 11. Drug interactions affecting the elimination of doxorubicin in the rat.
    Wosilait WD, Ryan MP.
    Res Commun Chem Pathol Pharmacol; 1987 Jun; 56(3):335-48. PubMed ID: 3628964
    [Abstract] [Full Text] [Related]

  • 12. Hepatic extraction, metabolism and biliary excretion of doxorubicin in the isolated perfused rat liver.
    Ballet F, Vrignaud P, Robert J, Rey C, Poupon R.
    Cancer Chemother Pharmacol; 1987 Jun; 19(3):240-5. PubMed ID: 3581417
    [Abstract] [Full Text] [Related]

  • 13. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Distribution and antitumor activity of adriamycin given in a high-dose and a repeated low-dose schedule to mice.
    Pacciarini MA, Barbieri B, Colombo T, Broggini M, Garattini S, Donelli MG.
    Cancer Treat Rep; 1978 May; 62(5):791-800. PubMed ID: 657163
    [Abstract] [Full Text] [Related]

  • 16. Cross-over study of pharmacokinetics and haematological toxicity of 4'-epi-doxorubicin and doxorubicin in cancer patients.
    Martini A, Moro E, Pacciarini MA, Tamassia V, Natale N, Piazza E.
    Int J Clin Pharmacol Res; 1984 May; 4(3):231-8. PubMed ID: 6593309
    [Abstract] [Full Text] [Related]

  • 17. Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine.
    Yoon EJ, Lee WI, Shim HJ, Lee SD, Kim WB, Yang J, Lee MG.
    Biopharm Drug Dispos; 1996 Jul; 17(5):373-420. PubMed ID: 8830976
    [Abstract] [Full Text] [Related]

  • 18. Disposition of 14C-labelled 4'-epidoxorubicin and doxorubicin in the rat. A comparative study.
    Arcamone F, Lazzati M, Vicario GP, Zini G.
    Cancer Chemother Pharmacol; 1984 Jul; 12(3):157-66. PubMed ID: 6584234
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Altered hepatic disposition of doxorubicin in the perfused rat liver at hyperthermic temperatures.
    Skibba JL, Jones FE, Condon RE.
    Cancer Treat Rep; 1982 Jun; 66(6):1357-63. PubMed ID: 7083240
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.